General Information of This Drug (ID: DMAEDQG)

Drug Name
EMODIN   DMAEDQG
Synonyms
emodin; 518-82-1; Emodol; Schuttgelb; Frangula emodin; Rheum emodin; Frangulic acid; 3-Methyl-1,6,8-trihydroxyanthraquinone; Archin; 1,3,8-trihydroxy-6-methylanthracene-9,10-dione; Persian Berry Lake; 1,3,8-Trihydroxy-6-methyl-9,10-anthraquinone; 6-Methyl-1,3,8-trihydroxyanthraquinone; C.I. Natural Yellow 14; 9,10-Anthracenedione, 1,3,8-trihydroxy-6-methyl-; 1,3,8-Trihydroxy-6-methylanthraquinone; 1,3,8-Trihydroxy-6-methyl-9,10-anthracenedione; 4,5,7-Trihydroxy-2-methylanthraquinone; UNII-KA46RNI6HN; C.I. 75440; NSC 622947
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Emodin + Idarubicin DCK3TK6 Idarubicin Glioblastoma? (Cell Line: T98G) [2]
------------------------------------------------------------------------------------

References

1 Naturally Occurring Anthraquinones as Potential Inhibitors of SARS-CoV-2 Main Protease: A Molecular Docking Study. May 7, 2020
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.